Meeting
2022 ASCO Annual Meeting
Prevalence of ultra-rare undifferentiated round cells sarcoma of bone and soft tissue after genomic classification.
Authors
Emanuela Palmerini
Osteoncology, Bone and Soft Tissue Sarcomas and Innovative Therapies, Orthopaedic Institute Rizzoli, Bologna, Italy
Emanuela Palmerini , Alberto Righi , Marta Sbaraglia , Elisa Carretta , Angelo Paolo Dei Tos , GIovanna Magagnoli , Marilena Cesari , Anna Paioli , Alessandra Longhi , Rossella Hakim , Piero Picci , Margherita Maioli , Stefania Cocchi , Katia Scotlandi , Davide Maria Donati , Toni Ibrahim , Marco Gambarotti
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Sarcoma
Track
Sarcoma
Sub Track
Soft Tissue Tumors
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 11559)
DOI
10.1200/JCO.2022.40.16_suppl.11559
Abstract #
11559
Poster Bd #
463
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Dose intensity and outcomes of VDC/IE chemotherapy for adolescent and adult patients with Ewing’s family sarcoma.
First Author: Danielle Klingberg
Poster
2016 ASCO Annual Meeting
BERNIE: Open-label, randomized, phase II study of bevacizumab plus chemotherapy in pediatric metastatic rhabdomyosarcoma (RMS) and non-rhabdomyosarcoma soft tissue sarcoma (NRSTS).
First Author: Julia C. Chisholm
Poster
2012 ASCO Annual Meeting
The BERNIE study: A phase II study evaluating addition of bevacizumab (Bv) to chemotherapy in children and adolescents with metastatic rhabdomyosarcoma (mRMS) and non-rhabdomyosarcoma soft tissue sarcoma (mNRSTS).
First Author: Julia C. Chisholm
Poster
2023 ASCO Annual Meeting
DCK expression by RNAseq as a potential biomarker of gemcitabine response in sarcoma.
First Author: David A. Liebner